Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Prospective Study in Laser Treatment of Pilonidal Cysts

NCT07314632 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-03-19
Last updated
2026-03-23

Condition(s) studied

Pilonidal Sinus

Study summary

The goal of this observational study is to evaluate the recurrence rate after laser treatment of pilonidal sinus within two years of the procedure in adult patients who require this procedure to treat their pilonidal sinus.

The main question it aims to answer is:

• Is there a clinical recurrence (presence of a fistula in the intergluteal cleft) 2 years after laser treatment of pilonidal sinus? Participants who undergo surgery as part of their regular medical care will answer survey questions about recurrence at 1 and 2 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients requiring laser surgery for pilonidal sinus, of any type (including recurrence after radical cure or laser treatment) * Patient able to understand the protocol and having given written informed consent to participate in the study, * Patient affiliated to the social security system or entitled to it. Exclusion Criteria: * Patient participating in another interventional clinical research protocol involving a drug or clinical investigation of a medical device * Patient already included in a research study * Patient under guardianship, conservatorship, or deprived of liberty * Patient under an activated future protection mandate * Patient under family authorization * Patient under judicial protection.

Primary outcome measure(s)

  • Clinical recurrence — 2 years post-operatively
    2-year recurrence rate after laser sinusectomy (presence of openings in the intergluteal cleft)

Trial sites (2)

FacilityCityRegionStatus
Clinique des Cèdres Cornebarrieu France Recruiting
CHD Vendée La Roche-sur-Yon France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07314632 on ClinicalTrials.gov ↗ ← All trials in France